5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(7-methanesulfonamidoheptyl)-4-methyl-1H-pyrazole-3-carboxamide | 1338604-27-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(7-methanesulfonamidoheptyl)-4-methyl-1H-pyrazole-3-carboxamide
• 英文别名: 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-[7-(methanesulfonamido)heptyl]-4-methylpyrazole-3-carboxamide
• CAS: 1338604-27-5
• 化学式: C₂₅H₂₉Cl₃N₄O₃S
• 分子量: 571.955
• InChiKey: OEODGEHOQCFPAS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.5
• 重原子数：
  36
• 可旋转键数：
  12
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  102
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(7-methanesulfonamidoheptyl)-4-methyl-1H-pyrazole-3-carboxamide 在 磺酰胺 作用下， 以 1,4-二氧六环 为溶剂， 反应 16.0h， 生成 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-[7-(sulfamoylamino)heptyl]-1H-pyrazole-3-carboxamide
  参考文献：
  名称：

  [EN] PYRAZOLE DERIVATIVES AS CANNABINOID RECEPTOR 1 ANTAGONISTS
  [FR] DÉRIVÉS DE PYRAZOLE UTILISÉS EN TANT QU'ANTAGONISTES DU RÉCEPTEUR DE TYPE 1 DES CANNABINOÏDES

  摘要：

  该发明提供了一种能够作为大麻素受体拮抗剂的化合物，其化学式如下：这些化合物可用于治疗与大麻素受体系统有关的疾病，如肥胖、肝病、糖尿病、疼痛和炎症。

  公开号：

  WO2012174362A1
• 作为产物：
  描述：

  1,7-二氨基庚烷 在 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 16.0h， 生成 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(7-methanesulfonamidoheptyl)-4-methyl-1H-pyrazole-3-carboxamide
  参考文献：
  名称：

  Towards rational design of cannabinoid receptor 1 (CB1) antagonists for peripheral selectivity

  摘要：

  CB1 receptor antagonists that are peripherally restricted were targeted. Compounds with permanent charge as well as compounds that have increased polar surface area were made and tested against CB1 for binding and activity. Sulfonamide and sulfamide with high polar surface area and good activity at CB1 were rationally designed and pharmacologically tested. Further optimization of these compounds and testing could lead to the development of a new class of therapeutics to treat disorders where the CB1 receptor system has been implicated. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.08.032

文献信息

• PYRAZOLE DERIVATIVES AS CANNABINOID RECEPTOR 1 ANTAGONISTS
  申请人：Fulp Alan Bradley

  公开号：US20140107157A1

  公开（公告）日：2014-04-17

  The invention provides compounds capable of acting as antagonists at cannabanoid receptors according to the following formula: Such compounds may be used to treat conditions for which the cannabinoid receptor system has been implicated, such as obesity, liver disease, diabetes, pain, and inflammation.

  本发明提供了一种能够作为大麻素受体拮抗剂的化合物，其化学式如下：这些化合物可用于治疗与大麻素受体系统有关的疾病，如肥胖症、肝脏疾病、糖尿病、疼痛和炎症等。
• US9133128B2
  申请人：——

  公开号：US9133128B2

  公开（公告）日：2015-09-15
• [EN] PYRAZOLE DERIVATIVES AS CANNABINOID RECEPTOR 1 ANTAGONISTS<br/>[FR] DÉRIVÉS DE PYRAZOLE UTILISÉS EN TANT QU'ANTAGONISTES DU RÉCEPTEUR DE TYPE 1 DES CANNABINOÏDES
  申请人：RES TRIANGLE INST

  公开号：WO2012174362A1

  公开（公告）日：2012-12-20

  The invention provides compounds capable of acting as antagonists at cannabanoid receptors according to the following formula: Such compounds may be used to treat conditions for which the cannabinoid receptor system has been implicated, such as obesity, liver disease, diabetes, pain, and inflammation.

  该发明提供了一种能够作为大麻素受体拮抗剂的化合物，其化学式如下：这些化合物可用于治疗与大麻素受体系统有关的疾病，如肥胖、肝病、糖尿病、疼痛和炎症。
• Towards rational design of cannabinoid receptor 1 (CB1) antagonists for peripheral selectivity
  作者：Alan Fulp、Katherine Bortoff、Yanan Zhang、Herbert Seltzman、Rodney Snyder、Rangan Maitra

  DOI：10.1016/j.bmcl.2011.08.032

  日期：2011.10

  CB1 receptor antagonists that are peripherally restricted were targeted. Compounds with permanent charge as well as compounds that have increased polar surface area were made and tested against CB1 for binding and activity. Sulfonamide and sulfamide with high polar surface area and good activity at CB1 were rationally designed and pharmacologically tested. Further optimization of these compounds and testing could lead to the development of a new class of therapeutics to treat disorders where the CB1 receptor system has been implicated. (C) 2011 Elsevier Ltd. All rights reserved.